JP2021038197A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021038197A5 JP2021038197A5 JP2020129449A JP2020129449A JP2021038197A5 JP 2021038197 A5 JP2021038197 A5 JP 2021038197A5 JP 2020129449 A JP2020129449 A JP 2020129449A JP 2020129449 A JP2020129449 A JP 2020129449A JP 2021038197 A5 JP2021038197 A5 JP 2021038197A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- administered
- clovalimab
- medicament according
- kurobarimabu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022036156A JP7749495B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19189436 | 2019-07-31 | ||
| EP19189436 | 2019-07-31 | ||
| EP20174781 | 2020-05-14 | ||
| EP20174781 | 2020-05-14 | ||
| EP20179590 | 2020-06-11 | ||
| EP20179590 | 2020-06-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036156A Division JP7749495B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021038197A JP2021038197A (ja) | 2021-03-11 |
| JP2021038197A5 true JP2021038197A5 (https=) | 2021-08-19 |
| JP7437260B2 JP7437260B2 (ja) | 2024-02-22 |
Family
ID=71846414
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129449A Active JP7437260B2 (ja) | 2019-07-31 | 2020-07-30 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
| JP2022036156A Active JP7749495B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036156A Active JP7749495B2 (ja) | 2019-07-31 | 2022-03-09 | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275071A1 (https=) |
| EP (1) | EP4003408A1 (https=) |
| JP (2) | JP7437260B2 (https=) |
| KR (2) | KR20240001329A (https=) |
| CN (2) | CN115137815A (https=) |
| AU (1) | AU2020319677A1 (https=) |
| CA (1) | CA3144921A1 (https=) |
| CR (1) | CR20220040A (https=) |
| IL (1) | IL288636A (https=) |
| MX (1) | MX2022001153A (https=) |
| TW (1) | TWI886139B (https=) |
| WO (1) | WO2021019033A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202404632A (zh) * | 2022-04-04 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PL3167888T3 (pl) | 2006-03-15 | 2024-08-26 | Alexion Pharmaceuticals, Inc. | Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| IL259256B2 (en) | 2015-12-18 | 2023-02-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
| EP3554543A4 (en) * | 2016-12-16 | 2020-09-02 | Samsung Bioepis Co., Ltd. | STABLE Aqueous ANTI-C5 ANTIBODY COMPOSITION |
| IL307593A (en) * | 2017-01-31 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
-
2020
- 2020-07-30 WO PCT/EP2020/071551 patent/WO2021019033A1/en not_active Ceased
- 2020-07-30 KR KR1020237043841A patent/KR20240001329A/ko not_active Ceased
- 2020-07-30 CA CA3144921A patent/CA3144921A1/en active Pending
- 2020-07-30 US US17/630,050 patent/US20220275071A1/en active Pending
- 2020-07-30 AU AU2020319677A patent/AU2020319677A1/en active Pending
- 2020-07-30 MX MX2022001153A patent/MX2022001153A/es unknown
- 2020-07-30 TW TW109125860A patent/TWI886139B/zh active
- 2020-07-30 KR KR1020207030732A patent/KR102618269B1/ko active Active
- 2020-07-30 CN CN202210474600.6A patent/CN115137815A/zh active Pending
- 2020-07-30 EP EP20747414.9A patent/EP4003408A1/en active Pending
- 2020-07-30 CN CN202080054192.8A patent/CN114466660A/zh active Pending
- 2020-07-30 CR CR20220040A patent/CR20220040A/es unknown
- 2020-07-30 JP JP2020129449A patent/JP7437260B2/ja active Active
-
2021
- 2021-12-02 IL IL288636A patent/IL288636A/en unknown
-
2022
- 2022-03-09 JP JP2022036156A patent/JP7749495B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nguyen et al. | Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration | |
| Chappelow et al. | Neovascular age-related macular degeneration: potential therapies | |
| AU2007238677B2 (en) | Use of IL-I antibodies for treating ophthalmic disorders | |
| JP6887212B2 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| TW202323296A (zh) | 組合療法 | |
| JP2004536072A (ja) | 種々の疾患の治療のための抗−ｎｇｆ抗体 | |
| JP7564347B2 (ja) | 多発性硬化症を治療するためのｌｏｕ０６４ | |
| CN112689512B (zh) | 用于治疗银屑病的组合物和方法 | |
| CN102753171A (zh) | 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物 | |
| JP2025514978A (ja) | 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用 | |
| KR20170131543A (ko) | 근위축성 측삭 경화증을 치료하기 위한 비오틴 | |
| LeBlanc et al. | Secretogranin III as a novel target for the therapy of choroidal neovascularization | |
| Luca et al. | A Phase 1 single-ascending-dose trial in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous pnt001, a novel mid-domain tau antibody targeting cis-pT231 tau | |
| WO2022049614A1 (ja) | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 | |
| JP7558306B2 (ja) | 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体 | |
| JP2021038197A5 (https=) | ||
| Liu et al. | Ginsenoside-Rh2 promotes functional recovery after spinal cord injury by enhancing TFEB-mediated autophagy | |
| Di Stefano et al. | Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study | |
| Li et al. | Nuciferine ameliorates blood-brain barrier disruption post-ischemic stroke via inhibiting the JAK2/STAT3 pathway | |
| JP2025529933A (ja) | ＡｃｔＲＩＩ抗体固定単位用量の治療 | |
| TW202339798A (zh) | Actrii抗體之治療 | |
| JP2021501213A (ja) | ＩｇＥ介在アレルギー性疾患の治療 | |
| TWI850365B (zh) | 治療克隆氏症(crohn's disease)的方法 | |
| JP7186214B2 (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| Nowak et al. | The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy |